• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

宫颈癌盆腔脏器清扫术后的生存情况:一项国家癌症数据库研究

Survival After Pelvic Exenteration for Cervical Cancer: A National Cancer Database Study.

作者信息

Graves Stephen, Seagle Brandon-Luke L, Strohl Anna E, Shahabi Shohreh, Nieves-Neira Wilberto

机构信息

Department of Obstetrics and Gynecology, Prentice Women's Hospital, Northwestern University, Feinberg School of Medicine, Chicago, IL.

出版信息

Int J Gynecol Cancer. 2017 Feb;27(2):390-395. doi: 10.1097/IGC.0000000000000884.

DOI:10.1097/IGC.0000000000000884
PMID:27984375
Abstract

OBJECTIVE

To determine overall survival (OS) and factors associated with OS after pelvic exenteration for cervical cancer.

METHODS

Women with cervical cancer who underwent exenteration (n = 517) were identified from the 1998 to 2011 National Cancer Database. Kaplan-Meier and multivariate Cox proportional-hazards survival analyses were performed to test for associations of potential explanatory variables with OS. Analyzed confounders included age, insurance status, income, distance from home to treatment center, stage, exenteration type, surgical margin status, and treatment with adjuvant radiation and/or chemotherapy.

RESULTS

Among the entire cohort with clinical follow-up (n = 313), median OS was 24 months. Stage (P = 2.5 × 10), lymph node status (P = 1.3 × 10), insurance status (P = 1.5 × 10), and histologic type (P = 0.04) were significantly associated with OS by the log-rank test. Unadjusted median OS was 24.2 and 61.8 months for women with squamous and adenocarcinoma histologies, respectively. By multivariate Cox regression, age, insurance status, stage, margin status, and adjuvant radiation were associated with OS. Histology was not independently associated with OS on multivariate regression. Among women with node-negative disease, median OS was 73.2 months.

CONCLUSIONS

Exenteration may be curative for more than half of women with node-negative cervical cancer. Stage, insurance status, lymph node status, and surgical margin are independently associated with differential OS after exenteration.

摘要

目的

确定宫颈癌盆腔脏器清除术后的总生存期(OS)以及与OS相关的因素。

方法

从1998年至2011年国家癌症数据库中识别出接受盆腔脏器清除术的宫颈癌女性患者(n = 517)。采用Kaplan-Meier法和多变量Cox比例风险生存分析来检验潜在解释变量与OS之间的关联。分析的混杂因素包括年龄、保险状况、收入、住所至治疗中心的距离、分期、盆腔脏器清除术类型、手术切缘状态以及辅助放疗和/或化疗情况。

结果

在有临床随访的整个队列(n = 313)中,中位OS为24个月。通过对数秩检验,分期(P = 2.5×10)、淋巴结状态(P = 1.3×10)、保险状况(P = 1.5×10)和组织学类型(P = 0.04)与OS显著相关。鳞状细胞癌和腺癌组织学类型的女性患者,未经调整的中位OS分别为24.2个月和61.8个月。通过多变量Cox回归分析,年龄、保险状况、分期、切缘状态和辅助放疗与OS相关。在多变量回归中,组织学类型与OS无独立相关性。在淋巴结阴性疾病的女性患者中,中位OS为73.2个月。

结论

盆腔脏器清除术可能治愈超过一半的淋巴结阴性宫颈癌女性患者。分期、保险状况、淋巴结状态和手术切缘与盆腔脏器清除术后的OS差异独立相关。

相似文献

1
Survival After Pelvic Exenteration for Cervical Cancer: A National Cancer Database Study.宫颈癌盆腔脏器清扫术后的生存情况:一项国家癌症数据库研究
Int J Gynecol Cancer. 2017 Feb;27(2):390-395. doi: 10.1097/IGC.0000000000000884.
2
Survival after pelvic exenteration for uterine malignancy: A National Cancer Data Base study.子宫恶性肿瘤盆腔脏器切除术术后生存率:一项国家癌症数据库研究。
Gynecol Oncol. 2016 Dec;143(3):472-478. doi: 10.1016/j.ygyno.2016.10.018. Epub 2016 Oct 17.
3
Rationality of FIGO 2018 IIIC cervical cancer according to local tumor and pelvic lymph node metastatic extent-a cohort study.根据局部肿瘤和盆腔淋巴结转移范围探讨2018年国际妇产科联盟(FIGO)IIIC期宫颈癌的合理性——一项队列研究
BMC Womens Health. 2025 Jul 4;25(1):308. doi: 10.1186/s12905-025-03846-5.
4
Survival after curative pelvic exenteration for primary or recurrent cervical cancer: a retrospective multicentric study of 167 patients.根治性盆腔脏器切除术治疗原发性或复发性宫颈癌的生存情况:167 例患者的回顾性多中心研究。
Int J Gynecol Cancer. 2014 Jun;24(5):916-22. doi: 10.1097/IGC.0b013e3182a80aec.
5
Open versus laparoscopic pelvic lymph node dissection in early stage cervical cancer: no difference in surgical or disease outcome.早期宫颈癌经腹与腹腔镜盆腔淋巴结清扫术的比较:手术和疾病结局无差异。
Int J Gynecol Cancer. 2012 Jan;22(1):107-14. doi: 10.1097/IGC.0b013e31822c273d.
6
Survival After Primary Debulking Surgery Compared With Neoadjuvant Chemotherapy in Advanced Ovarian Cancer: A National Cancer Database Study.晚期卵巢癌初次肿瘤细胞减灭术与新辅助化疗后的生存率比较:一项国家癌症数据库研究
Int J Gynecol Cancer. 2017 Oct;27(8):1610-1618. doi: 10.1097/IGC.0000000000001072.
7
Pattern of Care, Health Care Disparities, and Their Impact on Survival Outcomes in Stage IVB Cervical Cancer: A Nationwide Retrospective Cohort Study.IVB 期宫颈癌的治疗模式、卫生保健差异及其对生存结局的影响:一项全国性回顾性队列研究。
Int J Gynecol Cancer. 2018 Jun;28(5):1003-1012. doi: 10.1097/IGC.0000000000001264.
8
Comparison of Two Modern Survival Prediction Tools, SORG-MLA and METSSS, in Patients With Symptomatic Long-bone Metastases Who Underwent Local Treatment With Surgery Followed by Radiotherapy and With Radiotherapy Alone.两种现代生存预测工具 SORG-MLA 和 METSSS 在接受手术联合放疗和单纯放疗治疗有症状长骨转移患者中的比较。
Clin Orthop Relat Res. 2024 Dec 1;482(12):2193-2208. doi: 10.1097/CORR.0000000000003185. Epub 2024 Jul 23.
9
The 5-year overall survival of cervical cancer in stage IIIC-r was little different to stage I and II: a retrospective analysis from a single center.宫颈癌 IIIC-r 期 5 年总生存率与 I 期和 II 期无明显差异:单中心回顾性分析。
BMC Cancer. 2021 Feb 27;21(1):203. doi: 10.1186/s12885-021-07890-w.
10
Neoadjuvant chemotherapy plus surgery versus surgery for cervical cancer.新辅助化疗联合手术与单纯手术治疗宫颈癌的比较
Cochrane Database Syst Rev. 2012 Dec 12;12(12):CD007406. doi: 10.1002/14651858.CD007406.pub3.

引用本文的文献

1
Robotic-Assisted Pelvic Exenteration for Cervical Cancer: A Systematic Review and Novel Insights into Compartment-Based Imaging.机器人辅助宫颈癌盆腔脏器清除术:一项系统评价及基于分区成像的新见解
J Clin Med. 2024 Jun 24;13(13):3673. doi: 10.3390/jcm13133673.
2
A nomogram of preoperative indicators predicting lymph vascular space invasion in cervical cancer.预测宫颈癌淋巴血管间隙浸润的术前指标列线图。
Arch Gynecol Obstet. 2024 May;309(5):2079-2087. doi: 10.1007/s00404-024-07385-6. Epub 2024 Feb 15.
3
Gynecologic Oncology: Pelvic Exenteration for Advanced or Recurring Cervical Cancer - A Single Center Analysis.
妇科肿瘤学:晚期或复发性宫颈癌的盆腔脏器切除术——单中心分析
Cancer Diagn Progn. 2022 May 3;2(3):308-315. doi: 10.21873/cdp.10110. eCollection 2022 May-Jun.
4
Prognostic Analysis and Comparison of the 2014 and 2018 International Federation of Gynecology and Obstetrics Staging System on Overall Survival in Patients with Stage IIB-IVA Cervix Carcinoma.2014年与2018年国际妇产科联盟分期系统对IIB-IVA期宫颈癌患者总生存的预后分析及比较
Int J Womens Health. 2022 Mar 6;14:333-344. doi: 10.2147/IJWH.S348074. eCollection 2022.
5
The impact of nutritional risk factors and sarcopenia on survival in patients treated with pelvic exenteration for recurrent gynaecological malignancy: a retrospective cohort study.营养风险因素和肌肉减少症对复发性妇科恶性肿瘤盆腔廓清术患者生存的影响:一项回顾性队列研究。
Arch Gynecol Obstet. 2022 May;305(5):1343-1352. doi: 10.1007/s00404-021-06273-7. Epub 2021 Nov 3.
6
En bloc resection of cervical adenocarcinoma with late recurrence to the iliopsoas.宫颈腺癌大块切除术,术后髂腰肌复发。
BMJ Case Rep. 2021 Feb 18;14(2):e239466. doi: 10.1136/bcr-2020-239466.
7
Analysis of long-term outcomes in 44 patients following pelvic exenteration due to cervical cancer.44例因宫颈癌接受盆腔脏器清除术患者的长期预后分析。
World J Surg Oncol. 2020 Sep 2;18(1):234. doi: 10.1186/s12957-020-01997-3.
8
Prognostic value of lymphovascular space invasion in patients with early stage cervical cancer in Jilin, China: A retrospective study.中国吉林早期宫颈癌患者中脉管间隙浸润的预后价值:一项回顾性研究
Medicine (Baltimore). 2019 Oct;98(40):e17301. doi: 10.1097/MD.0000000000017301.
9
Factors associated with post-relapse survival in patients with recurrent cervical cancer: the value of the inflammation-based Glasgow Prognostic Score.与复发性宫颈癌患者复发后生存相关的因素:基于炎症的格拉斯哥预后评分的价值。
Arch Gynecol Obstet. 2019 Apr;299(4):1055-1062. doi: 10.1007/s00404-018-4993-0. Epub 2018 Dec 10.